Definium Therapeutics Inc (DFTX)
R&D Expense Growth
17.31%
Quarterly · Period ending:
DFTX R&D Expense Growth
Latest reported17.31%period ending
Latest reported17.31%period ending
DFTX Quarterly R&D Growth (QoQ) (0.00% → 17.31%)
Latest values, visible window
High-resolution chart · PNG
DFTX r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 17.3103% | |
| 23.7553% | |
| 8.2091% | |
| 3.9216% | |
| 27.6234% | |
| 7.3441% | |
| 26.5941% | |
| 17.3643% | |
| 31.0163% | |
| -3.1873% | |
| -12.5502% | |
| -10.6517% | |
| 17.2871% | |
| 42.684% | |
| 13.613% | |
| -16.6631% | |
| -8.9347% | |
| -5.8991% | |
| 20.6675% | |
| 11.7042% | |
| 18.5087% | |
| -16.4766% | |
| 52.6956% | |
| 97.8519% | |
| 49.7504% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |